Touchlight announced a license agreement with GSK. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA, doggybone DNA, technology for the development and production of mRNA-based products. The license will enable GSK to access the leading technology for rapid and scalable GMP production of DNA, with the potential to accelerate substantially the production of multivalent mRNA vaccines, including for use against seasonal epidemics and pandemic threats. While financial terms of the agreement are undisclosed, the deal includes an upfront payment, ongoing technology access fees, clinical and regulatory milestone payments and royalties on GSK’s mRNA products manufactured with Touchlight’s enzymatic dbDNA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Down 60% in 3 Years, Will Moderna Stock (NASDAQ:MRNA) Fall Further?
- GSK reports EMA accepts marketing authoriaation application for Blenrep combos
- GSK Pharma call volume above normal and directionally bullish
- GSK begins shipping influenza vaccine doses for 2024-25 season
- GSK begins shipping doses of its trivalent influenza vaccines in U.S.